Publication:
Novel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II-Induced Microvascular Dysfunction

dc.contributor.authorsSenchenkova, Elena Y.; Russell, Janice; Yildirim, Alper; Granger, D. Neil; Gavins, Felicity N. E.
dc.date.accessioned2022-03-14T09:14:48Z
dc.date.accessioned2026-01-11T17:13:07Z
dc.date.available2022-03-14T09:14:48Z
dc.date.issued2019-04
dc.description.abstractHypertension is an established risk factor for subsequent cardiovascular diseases, with Ang II (angiotensin II) playing a major role in mediating thrombotic and inflammatory abnormalities. Although T cells and IL-6 (interleukin-6) play an important role in adaptive immune responses, little is known about their role(s) in the thromboinflammatory responses associated with Ang II. Here we show using intravital microscopy coupled with the light/dye injury model that Rag-1 deficient (Rag-1(-/-)) and IL-6 deficient (IL-6(-/-)) mice are afforded protection against Ang II-induced thrombosis. Blocking IL-6 receptors (using CD126 and gp130 antibodies) significantly diminished Ang II-mediated thrombosis and inflammatory cell recruitment in mice. Furthermore, the adoptive transfer of IL-6(-/-)-derived T cells into Rag-1(-/-) mice failed to accelerate Ang II-induced thrombosis compared with Rag-1(-/-)mice reconstituted with wild-type-derived T cells, suggesting T cell IL-6 mediates the thrombotic abnormalities associated Ang II hypertension. Interestingly, adoptive transfer of WT T cells into Rag-1(-/-)/Ang II mice resulted in increased numbers of immature platelets, which constitutes a more active platelet population, that is, prothrombotic and proinflammatory. To translate our in vivo findings, we used clinical samples to demonstrate that IL-6 also predisposes platelets to an interaction with collagen receptors, thereby increasing the propensity for platelets to aggregate and cause thrombosis. In summary, we provide compelling evidence for the involvement of IL-6, IL-6R, and T-cell-dependent IL-6 signaling in Ang II-induced thromboinflammation, which may provide new therapeutic possibilities for drug discovery programs for the management of hypertension.
dc.identifier.doi10.1161/HYPERTENSIONAHA.118.12286
dc.identifier.eissn1524-4563
dc.identifier.issn0194-911X
dc.identifier.pubmed30739537
dc.identifier.urihttps://hdl.handle.net/11424/242844
dc.identifier.wosWOS:000469351200011
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofHYPERTENSION
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectangiotensin II
dc.subjecthypertension
dc.subjectinterleukin-6
dc.subjectinflammation
dc.subjectthrombosis
dc.subjectIN-VIVO BIOTINYLATION
dc.subjectRETICULATED PLATELETS
dc.subjectINTERFERON-GAMMA
dc.subjectHYPERTENSION
dc.subjectTHROMBOSIS
dc.subjectRECEPTOR
dc.subjectSYSTEM
dc.subjectLEUKOCYTE
dc.subjectACTIVATOR
dc.subjectINFLAMMATION
dc.titleNovel Role of T Cells and IL-6 (Interleukin-6) in Angiotensin II-Induced Microvascular Dysfunction
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage838
oaire.citation.issue4
oaire.citation.startPage829
oaire.citation.titleHYPERTENSION
oaire.citation.volume73

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
978.77 KB
Format:
Adobe Portable Document Format